Orna Therapeutics Shares Exciting Advances in CAR Therapy
Orna Therapeutics, a cutting-edge biotechnology firm, has revealed important plans surrounding its innovative in vivo CAR therapy tailored for tackling autoimmune diseases. The company is scheduled to present at the distinguished American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, which signifies an important milestone in the advancement of its therapeutic strategies.
Insights from the Presentation
During this anticipated presentation, the audience can expect to gain insights into Orna's promising data regarding their advanced panCAR™ programs. The CEO, Joseph Bolen, Ph.D., expressed enthusiasm about showcasing findings demonstrating how their specialized platform employs circular RNA (oRNA) technology alongside leading lipid nanoparticle (LNP) delivery systems. This innovative approach has the potential to create sustainable pharmacodynamic effects while maintaining robust protein expression through multiple administrations.
Scientific Innovations at ASGCT
As Orna Therapeutics prepares to present vital new data at the ASGCT, their focus on effective healthcare solutions becomes clear. The session will explore Orna's development of the CD19 autoimmune panCAR program, aiming to enter clinical testing in the near future. This initiative represents a significant leap forward in treating various diseases driven by B cells, thus transforming patient outcomes.
Key Presentation Details
The details of Orna's upcoming presentation include:
Title: In Vivo panCAR™ Therapy Using Circular RNA for the Treatment of Autoimmune Disease
Speaker: Megan Hoban, Ph.D., panCAR Program Lead, Orna Therapeutics
Date/Time: Thursday, 8:00 AM – 9:45 AM CDT
Session Name: Cellular and Gene Therapies for Autoimmune Disease
Location: Room 388-390
Unveiling Potential with CD19
The emerging data will illustrate how Orna's CD19 panCAR platform is capable of inducing sustained B cell depletion in non-human primate models. This advancement suggests a pathway to improve treatment protocols significantly for a range of autoimmune complications, illustrating Orna's ongoing commitment to innovative therapy solutions.
About Orna Therapeutics
Orna Therapeutics is firmly established in the realm of biotechnology, focusing on the design and application of advanced circular RNA (oRNA) therapeutics. This transformative approach positions them at the forefront of RNA medicine, aiming to address diseases throughout the body. Their unique oRNA transcripts offer distinct advantages, such as simplified production processes, improved formulation capabilities, and enhanced protein expression levels.
With a dedication to improving healthcare outcomes, Orna strives to unlock the vast potential of RNA technologies. Their state-of-the-art LNP delivery systems and comprehensive therapeutic editing programs uniquely qualify them to bring forth groundbreaking RNA-based treatments.
Connect with Orna Therapeutics
For more information about their impactful projects and ongoing research, visit Orna Therapeutics' official website and connect through their social media platforms.
Frequently Asked Questions
What is the focus of Orna Therapeutics?
Orna Therapeutics specializes in developing innovative RNA-based therapies targeting autoimmune diseases and oncology diseases.
When is Orna's presentation at the ASGCT?
The presentation is scheduled for Thursday at 8:00 AM CDT during the ASGCT Annual Meeting.
Who will be presenting for Orna Therapeutics?
Megan Hoban, Ph.D., will be leading the presentation of the CD19 panCAR therapy.
What innovation does Orna Therapeutics offer in RNA therapy?
Orna utilizes circular RNA technology, which creates a more efficient therapeutic delivery process.
How does Orna's therapy potentially benefit patients?
Orna's therapies have the potential to achieve sustained effects and improved patient outcomes across various autoimmune diseases.
